FDA grants accelerated approval to Nelkarmi for previously treated ALK-positive lung cancer
Posted on November 18, 2026
GSK has received U.S. Food and Drug Administration accelerated approval for Nelkarmi in adults with previously treated, locally advanced or metastatic ALK-positive non-small cell lung cancer.
The approval covers patients who have received either alectinib as their only prior ALK tyrosine kinase inhibitor, or at least two previous ALK inhibitors together with platinum-based chemotherapy.
Nelkarmi, also known as neladalkib, is a next-generation ALK-selective tyrosine kinase inhibitor designed to address treatment resistance, central nervous system disease and tolerability challenges in ALK-positive lung cancer.
The approval was granted ahead of the FDA’s original target action date of November 27, 2026.
It follows previous Breakthrough Therapy and Orphan Drug designations for the treatment.
The decision was supported by results from the Phase I/II ALKOVE-1 study.
Among patients who had previously received alectinib as their only ALK inhibitor, the confirmed overall response rate was 49%, with 33 of 67 patients responding.
Among responders in this group, 76% maintained their response for at least six months and 52% maintained it for at least 12 months.
In patients who had previously received at least two ALK inhibitors and platinum-based chemotherapy, the confirmed overall response rate was 32%, with 50 of 155 patients responding.
Among responders in this more heavily pretreated population, 69% maintained their response for at least six months and 51% for at least 12 months.
Nelkarmi also demonstrated activity in patients with measurable central nervous system metastases.
The intracranial overall response rate was 55% among patients previously treated with alectinib as their only ALK inhibitor.
This included complete intracranial responses in 25% of patients.
Among patients who had received at least two ALK inhibitors and chemotherapy, the intracranial response rate was 26%, including complete responses in 11%.
Tony Wood, Chief Scientific Officer at GSK, said Nelkarmi was designed to provide broad coverage of ALK resistance mutations while maintaining penetration into the central nervous system.
He said the approval provides another treatment option for patients who may require sequential targeted therapies over several years.
The most common adverse reactions, occurring in at least 20% of patients, included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, oedema and fatigue.
Permanent treatment discontinuation due to adverse reactions occurred in 5% of patients.
Hepatotoxicity was the most common adverse reaction leading to permanent discontinuation.
ALKOVE-1 is a global single-arm Phase I/II study evaluating neladalkib in patients with ALK-positive NSCLC and other ALK-positive solid tumours.
The trial enrolled 700 patients overall, with 222 previously treated ALK-positive NSCLC patients included in the primary efficacy analysis supporting the FDA approval.
The main efficacy measures were confirmed overall response rate and duration of response assessed by blinded independent central review.
Nelkarmi was added to GSK’s portfolio through its recent acquisition of Nuvalent.
The drug is also being evaluated in the Phase III ALKAZAR trial in treatment-naïve ALK-positive NSCLC and in other ALK-positive solid tumours.
Related Topics and Keywords
Accelerated Approval, alectinib, ALK Inhibitor, ALK-positive NSCLC, ALKAZAR, ALKOVE-1, Biopharma, brain metastases, clinical trials, CNS metastases, duration of response, FDA, GSK, lung cancer, neladalkib, Nelkarmi, non-small cell lung cancer, Oncology, overall response rate, pharma news, Phase I, Phase II, phase III, TKI, Tyrosine Kinase Inhibitor
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy















